Viridian Therapeutics, Inc.(VRDN)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VRDN Viridian Therapeutics, Inc.

休市中 05-17 16:00:00 EDT

13.45

-1.18

-8.07%

盘后13.45

+0.000.00%

16:20 EDT

最高14.76	最低13.39	成交量110.69万
今开14.60	昨收14.63	日振幅9.33%
总市值8.58亿	流通市值6.68亿	总股本6,382万
成交额1,526万	换手率2.23%	流通股本4,964万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"VRDN","market":"US","secType":"STK","nameCN":"Viridian Therapeutics, Inc.","latestPrice":13.45,"timestamp":1715976000000,"preClose":14.63,"halted":0,"volume":1106910,"hourTrading":{"tag":"盘后","latestPrice":13.45,"preClose":13.45,"latestTime":"16:20 EDT","volume":16299,"amount":219217.51,"timestamp":1715977200398},"delay":0,"floatShares":49635046,"shares":63822468,"eps":-4.409268,"marketStatus":"休市中","marketStatusCode":7,"change":-1.18,"latestTime":"05-17 16:00:00 EDT","open":14.6,"high":14.755,"low":13.39,"amount":15257554.45956,"amplitude":0.093301,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.409268,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1716192000000},"adr":0,"adjPreClose":14.63,"postHourTrading":{"tag":"盘后","latestPrice":13.45,"preClose":13.45,"latestTime":"16:20 EDT","volume":16299,"amount":219217.51,"timestamp":1715977200398},"volumeRatio":1.513611716270998},"requestUrl":"/m/hq/s/VRDN","defaultTab":"news","newsList":[{"id":"2433447267","title":"Viridian Therapeutics Inc    预计每股亏损 1.10 美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2433447267","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2433447267?lang=zh_cn&edition=full","pubTime":"2024-05-06 22:15","pubTimestamp":1715004917,"startTime":"0","endTime":"0","summary":"   * Viridian Therapeutics Inc    将于5月8日公布截至2024年3月31日的财报，预计该公司的季度收入将出现下降。* 根据LSEG的数据，11位分析师的平均预期显示，这家总部位于马萨诸塞州沃尔瑟姆的公司的营收将从去年同期的9.8万美元下降27.4%，至7.118万美元。* LSEG 分析师对 Viridian Therapeutics Inc 的平均预期是每股亏损 1.10 美元。* 华尔街对 Viridian Therapeutics Inc 的 12 个月目标价中位数为 37.00 美元，高于其上次收盘价 15.40 美元。5月6日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2421025459","title":"BUZZ-竞争对手中外制药的数据不尽如人意，Immunovant 和 Argenx 的业绩上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2421025459","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2421025459?lang=zh_cn&edition=full","pubTime":"2024-03-22 00:04","pubTimestamp":1711037051,"startTime":"0","endTime":"0","summary":"    3月21日 - ** 在日本中外制药公司  报告了其自身免疫性疾病药物satralizumab的后期数据后，Immunovant  的股价上涨2.5%至32.36美元，在美国上市的Argenx  的股价上涨12.3%至401美元。** 券商 Stifel 表示，由于该药物之前的研究数据令人印象深刻，因此该数据一直是 ARGX 和 IMVT 的主要障碍。** ARGX公司的Vyvgrat已被批准用于治疗这种疾病，而IMVT公司的实验性疗法正处于后期研究阶段。** Viridian Therapeutics    和 Tourmaline Bio    的股价分别下跌了 38.8% 和 38.8%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2404580940","title":"BUZZ-Viridian Therapeutics 因发行 1.5 亿美元股票而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2404580940","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2404580940?lang=zh_cn&edition=full","pubTime":"2024-01-18 22:21","pubTimestamp":1705587693,"startTime":"0","endTime":"0","summary":"    1月18日 - ** Viridian Therapeutics   股价在隔夜后续定价后下跌 4.7%，盘前报 21.26 美元。** 该公司在周三晚些时候以 21 美元的价格出售了  ~710 万股股票，筹集了 1.5 亿美元资金，用于临床开发项目、营运资金和一般用途。** 发行价较上一次销售折价 5.9** Viridian 有多种候选药物可用于治疗甲状腺眼病，拥有约 5260 万股流通股，市值约为 12 亿美元。** 2023 年股价下跌 25%，但截至周三，过去 3 个月股价已上涨近 90** Jefferies 和 Leerink Partners 担任股票发行的联席首席簿记管理人","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2391169949","title":"韦德布什：2024年买这些生物科技股吧","url":"https://stock-news.laohu8.com/highlight/detail?id=2391169949","media":"新浪财经","top":-1,"share":"https://www.laohu8.com/m/news/2391169949?lang=zh_cn&edition=full","pubTime":"2023-12-15 22:46","pubTimestamp":1702651602,"startTime":"0","endTime":"0","summary":"进入2024年，韦德布什认为生物技术行业早该恢复正增长了，特别是在中小型股。韦德布什在2024年的热门选择包括Ascendis Pharma、Neurocrine Biosciences和Sarepta Therapeutics。韦德布什认为，生物技术在10月份达到了最低点，随着更多的成功项目，该行业在2024年内可能会走高。韦德布什指出，尽管2023年给生物技术投资者带来了许多挑战，但估值过高并不是其中之一，资本市场仍然对生物技术公司开放。韦德布什继续认为，到2024年，这种情况将继续存在。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023121522491583fc9125&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023121522491583fc9125&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.viridiantherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0324},{"period":"1month","weight":-0.1081},{"period":"3month","weight":-0.2765},{"period":"6month","weight":-0.153},{"period":"1year","weight":-0.4041},{"period":"ytd","weight":-0.3825}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0577},{"period":"3month","weight":0.0599},{"period":"6month","weight":0.1745},{"period":"1year","weight":0.2629},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Viridian Therapeutics, Inc.于2014年6月17日在特拉华州成立，该公司是一家生物制药公司，专注于研究和开发针对严重和罕见疾病的潜在最佳药物。该公司瞄准的是竞争不激烈的疾病领域，在这些领域，已上市的疗法往往为提高疗效、安全性或给药便利性留出空间。该公司认为，第一代药物很少代表最佳解决方案，特别是在罕见病领域，而且有潜力开发差异化、同类最佳的药物，从而改善患者的治疗效果、减少副作用、提高生活质量、扩大市场准入和加强市场竞争。该公司正在开发三种候选产品：VRDN-001、VRDN-002和VRDN-003，这些产品正在开发中，用于静脉注射或皮下注射，以治疗患有甲状腺眼病（TED）的患者。该公司最先进的项目VRDN-001是一种靶向IGF-1R的差异化人源化单克隆抗体，用于治疗TED。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.315821},{"month":2,"riseRate":0.2,"avgChangeRate":-0.068987},{"month":3,"riseRate":0.3,"avgChangeRate":-0.074769},{"month":4,"riseRate":0.6,"avgChangeRate":0.030899},{"month":5,"riseRate":0.3,"avgChangeRate":-0.012349},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.003019},{"month":7,"riseRate":0.4,"avgChangeRate":-0.042819},{"month":8,"riseRate":0.1,"avgChangeRate":-0.091226},{"month":9,"riseRate":0.3,"avgChangeRate":-0.087401},{"month":10,"riseRate":0.2,"avgChangeRate":-0.053633},{"month":11,"riseRate":0.6,"avgChangeRate":0.153546},{"month":12,"riseRate":0.4,"avgChangeRate":-0.070141}],"exchange":"NASDAQ","name":"Viridian Therapeutics, Inc.","nameEN":"Viridian Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Viridian Therapeutics, Inc.(VRDN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Viridian Therapeutics, Inc.(VRDN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Viridian Therapeutics, Inc.,VRDN,Viridian Therapeutics, Inc.股票,Viridian Therapeutics, Inc.股票老虎,Viridian Therapeutics, Inc.股票老虎国际,Viridian Therapeutics, Inc.行情,Viridian Therapeutics, Inc.股票行情,Viridian Therapeutics, Inc.股价,Viridian Therapeutics, Inc.股市,Viridian Therapeutics, Inc.股票价格,Viridian Therapeutics, Inc.股票交易,Viridian Therapeutics, Inc.股票购买,Viridian Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Viridian Therapeutics, Inc.(VRDN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Viridian Therapeutics, Inc.(VRDN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况